Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16426121 | 0.79 | ENPP2 (0.46) | ENPP2CA2CA1TSHRLPL | |
| SCHEMBL2010727 | 0.77 | TP53 (0.52) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL423468 | 0.77 | ENPP2 (0.44) | ENPP2CA2CA1TSHRTTR | |
| SCHEMBL24165 | 0.77 | TTR (0.57) | ENPP2CA2CA1TSHRTTR | |
| SCHEMBL309397 | 0.77 | CA3 (0.52) | ENPP2CA2CA1TTR | |
| SCHEMBL306345 | 0.77 | TSHR (0.52) | ENPP2CA2CA1TSHRTTR | |
| SCHEMBL3791258 | 0.77 | ALOX15 (0.52) | ENPP2CA2CA1TSHRLPL | |
| SCHEMBL16654491 | 0.77 | CA2 (0.48) | ENPP2CA2CA1TSHRLPL | |
| SCHEMBL792416 | 0.77 | TSHR (0.48) | ENPP2CA2CA1TSHRLPL | |
| SCHEMBL29952333 | 0.77 | TSHR (0.52) | ENPP2CA2CA1TSHRTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120904648-A | Polylactic acid color master batch and preparation method thereof | 丙烽(安徽)科技有限公司 | 2025-11-07 | — | — | CN | disclosed |
| WO-2025053379-A1 | NOVEL COMPOUND AND USE THEREOF FOR TREATING PSORIASIS | 광주과학기술원 | 2025-03-13 | — | — | WO | disclosed |
| WO-2025037870-A1 | BENZOFURAN COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASES AND CANCER METASTASIS | 한국생명공학연구원 | 2025-02-20 | — | — | WO | disclosed |
| EP-3199558-B1 | COMPOUND HAVING FOUR POLYMERIZABLE GROUPS, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORP (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-2842974-B1 | COMPOUND HAVING FOUR POLYMERIZABLE GROUPS, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2019-03-13 | — | — | EP | disclosed |
| EP-3199558-A1 | COMPOUND HAVING FOUR POLYMERIZABLE GROUPS, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC Corporation (JP) | 2017-08-02 | — | — | EP | disclosed |
| EP-3168219-A1 | PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYL METHYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9617477-B2 | Compound having four polymerizable groups, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-04-11 | — | — | US | disclosed |
| US-9617477-B2 | Compound having four polymerizable groups, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-04-11 | — | — | US | disclosed |
| US-9617477-B2 | Compound having four polymerizable groups, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-04-11 | — | — | US | disclosed |
| EP-2473504-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20130277609-A1 | COMPOUND HAVING FOUR POLYMERIZABLE GROUPS, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130277609-A1 | COMPOUND HAVING FOUR POLYMERIZABLE GROUPS, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130277609-A1 | COMPOUND HAVING FOUR POLYMERIZABLE GROUPS, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20120088737-A2 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2012-04-12 | — | — | US | disclosed |
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-04-07 | — | — | US | disclosed |
| WO-2011028947-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | SLC9A3, NHERF1, SLC9A2 | ENPP2 842/4885CA2 516/4885CA1 3641/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | ENPP2 1920/4885CA2 1992/4885CA1 3273/4885 |
| US-20120088737-A2 | NOVEL ACYL GUANIDINE DERIVATIVES | SLC9A3, NHERF1, SLC9A2 | ENPP2 842/4885CA2 516/4885CA1 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.